OncoSil Medical
(ASX:OSL) is developing an implantable radiotherapy device for the treatment of inoperable pancreatic and liver cancer.
OncoSil™ is created by melting up to 5% phosphorous in liquid silicon in a furnace. The resultant molten liquid is shattered into small particles using sterile water. The particles are graded by size and 30 micron particles are selected for further use.
The company has had discussions with the FDA and says its is ready by the end of the year to file for an FDA IDE. Earlier this year Oncosil filed for a CE Mark for European approval.
